FIELD: biochemistry.
SUBSTANCE: invention relates to a bispecific antibody against PD-1/CD3. Also a pharmaceutical composition for the prevention, suppression of symptoms of progression or recurrence of autoimmune diseases, using the specified antibody is disclosed.
EFFECT: invention allows to carry out effective prophylaxis, suppress symptoms of progression or recurrence of autoimmune diseases.
36 cl, 19 dwg, 15 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
ANTIBODY PURIFICATION | 2019 |
|
RU2812161C2 |
LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
Authors
Dates
2023-05-16—Published
2019-02-08—Filed